New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
10:00 EDTSBS, DLAKY, EPB, BZH, TRMB, OHI, HRL, CJES, BNPQY, VE, NGLS, MM, HOG, BMY, USBOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BNP Paribas (BNPQY) downgraded to Neutral from Overweight at HSBC... Beazer Homes (BZH) downgraded to Neutral from Buy at Sterne Agee... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Barclays... C&J Energy (CJES) downgraded to Equal Weight at Stephens... El Paso Pipeline (EPB) downgraded to Sell from Neutral at Goldman... Harley-Davidson (HOG) downgraded to Market Perform from Strong Buy at Raymond James... Hormel Foods (HRL) downgraded at Credit Suisse... Lufthansa (DLAKY) downgraded to Equal Weight from Overweight at Barclays... Millennial Media (MM) downgraded at Evercore... Omega Healthcare (OHI) downgraded to Neutral from Buy at Goldman... Saneamento Basico (SBS) downgraded to Sector Perform from Outperform at Scotia... Targa Resources Partners (NGLS) downgraded to Equal Weight at Barclays... Trimble (TRMB) downgraded to Neutral from Buy at Janney Capital... U.S. Bancorp (USB) downgraded at RW Baird... Veolia Environment (VE) downgraded to Equal Weight from Overweight at Morgan Stanley.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 23, 2015
15:28 EDTHRLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Analog Devices (ADI), consensus 83c... Hormel Foods (HRL), consensus 69c... Dollar Tree (DLTR), consensus 53c... Campbell Soup (CPB), consensus 76c... Signet Jewelers (SIG), consensus 39c... Tiffany (TIF), consensus 75c... Valspar (VAL), consensus $1.31... Patterson Companies (PDCO), consensus 60c... Eaton Vance (EV), consensus 59c...Burlington Stores (BURL), consensus 23c... Cracker Barrel (CBRL), consensus $1.59.
15:00 EDTBMYFDA approves Bristol-Myers drug to treat form of kidney cancer
Subscribe for More Information
13:33 EDTHRLHormel Foods volatility flat into Q4 and outlook
Subscribe for More Information
12:45 EDTHOGHarley-Davidson at York vehicle operations approve new labor agreement
Subscribe for More Information
10:41 EDTDLAKYLufthansa faces more strikes on Thursday, Friday from cabin crew, Reuters says
Subscribe for More Information
07:49 EDTHOGHarley-Davidson management is too optimistic on a recovery, says Barclays
Barclays analyst Felicia R. Hendrix believes Harley-Davidson's management is too optimistic near-term on a recovery. Hendrix said used bikes continues to outpace new sales, recent product launches have generated lower than expected "mindshare" among core customers. and competition is growing their presence. The analyst recommends stating on the sidelines until Harley-Davidson can demonstrate sustainable growth.
November 20, 2015
10:00 EDTTRMBOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: (FLWS) upgraded to Buy from Hold at Noble Financial... Diageo (DEO) upgraded to Overweight from Neutral at JPMorgan... Dollar General (DG) upgraded to Buy from Hold at BB&T... Intel (INTC) upgraded on positive checks at JMP Securities... Mazor Robotics (MZOR) upgraded to Buy from Neutral at Sterne Agee CRT... Star Bulk Carriers (SBLK) upgraded to Neutral from Sell at UBS... Trimble (TRMB) upgraded to Buy from Neutral at Goldman.
05:51 EDTBNPQYBNP Paribas to pay $59.8M in Swiss bank settlement, Bloomberg reports
BNP Paribas has agreed to pay $59.8M and revealed Swiss banking secrets in detail to avoid U.S. prosecution, reports Bloomberg. Some of the secrets include assets restructured into Liechtenstein-linked insurance policies, and a banker who agreed to communicate with one U.S. client by faxes or calls to a prepaid mobile phone. KBL and Bank CIC have also joined the program, paying $18.8M and $3.3M respectively. Reference Link
05:46 EDTBNPQYBNP Paribas dedicates EUR 15B in financing for renewable energy
Subscribe for More Information
November 19, 2015
18:31 EDTTRMBTrimble upgraded to Buy from Neutral at Goldman
Goldman analyst Jerry Revich upgraded Trimble to Buy from Neutral and maintained his $26 price target based on the company's extension of its Building Point distribution network, management's focus on cost reductions, and the company's key distribution advantage.
November 18, 2015
12:01 EDTBMYBristol-Myers Squibb says Opdivo data shows 'superior' overall survival
Subscribe for More Information
08:55 EDTUSBMorgan Stanley exec sees Q4 not much better than Q3 for banks, DJ reports
Morgan Stanley (MS) Institutional Securities President Colm Kelleher cautioned that fixed-income markets "still seem subdued," according to Dow Jones, citing his comments at an investment conference. Morgan Stanley was among the banks that reported lower revenue from fixed-income, currency and commodities trading during the third quarter and Kelleher said he doesn't think "the fourth quarter is going to be much better," the report noted. Large bank peers to Morgan Stanley include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
08:11 EDTBMYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 17, 2015
10:47 EDTBMYBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
November 16, 2015
17:18 EDTOHIOmega Healthcare files to sell common stock for holders, no amount given
Subscribe for More Information
17:05 EDTBMYBristol-Myers announces FDA accepts for priority review sBLA for Opdivo
Bristol-Myers Squibb Company announced that the U.S. FDA has accepted for filing and priority review a supplemental Biologics License Application for Opdivo for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. The FDA previously granted Opdivo Breakthrough Therapy Designation for this indication, underscoring the critical need for new treatment options for patients with advanced RCC who have received prior therapy. The projected FDA action date is March 16, 2016.
16:46 EDTNGLSTarga Resources says COO Heim to step down
Subscribe for More Information
07:00 EDTBMYBristol-Myers announces data from Phase 3 ALLY-3+ trial for Daklinza
Bristol-Myers announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a regimen of Daklinza in combination with sofosbuvir and ribavirin in genotype 3 hepatitis C patients with advanced fibrosis or cirrhosis, for treatment durations of 12 and 16 weeks. This patient population is one of the most difficult to treat, among whom sustained virologic response rates, or cure, have proved harder to achieve. The results show that 100% of patients in the advanced fibrosis cohort achieved SVR12 in both the 12- and 16-week arms of the study. SVR12 rates were 83% and 89% in patients with cirrhosis in the 12- and 16-week arms, respectively.
November 12, 2015
18:30 EDTSBSSABESP reports Q3 operating revenue up 13.2% y-o-y to R$3.2B
Subscribe for More Information
06:12 EDTUSBMorgan Stanley to offer wealth management clients savings accounts, Reuters says
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use